Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001704
Chunk: 36

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 36
---
 company estimates. Not independently verified. 1 Based on 202 4 U.S. adult hepatitis B vaccines net sales, adjusted for company estimates regarding HEPLISAV - B dosing regimen and pricing. 2 Internal estimate. Segment expansions assumes 50% of ACIP universal growth from Retail, 35% from IDN/Large Clinics and 15% fr o m Small Clinics/Ind. No ACIP universal growth assumed in Dialysis or Other (Dept of Corrections, Occupational Health), adjusted for company estimates regarding HEPLISAV - B dos ing regimen and pricing. 3 The 4 - dose regimen for the dialysis population is not a currently approved regimen; ​safety and effectiveness have not been est ablished in patients on hemodialysis. 4 Includes IDNs and certain large clinics which are prioritized by our salesforce HEPLISAV - B Market Opportunity Expected to Grow to Over $900 M in U.S. by 2030 © Copyright DYNAVAX 2025 HEPLISAV - B is the market share leader in projected largest growth segments (Retail and Prioritized IDNs) Strategy to Achieve 60% Market Share for HEPLISAV - B by 2030E • Maximize total addressable market focused on top retailers and IDNs based on the ACIP Universal Recommendation • Leverage foundational commercial asset to support company growth and pipeline development ​ HEPLISAV - B Market Share in Prioritized IDN/Clinics 5 3 % (Q 1 202 5 ) HEPLISAV - B Market Share in Retail 5 8 % (Q 1 202 5 ) 2030 Projected Market Size: >$900M 2 2024 Market Size: ~$615M 1 Prioritized IDN/Clinics⁴ 35% Retail 26% [CATEGO RY NAME] 22% Other 10% Dialysis³ 6% Prioritized IDN/Clinics⁴ 30% Retail 40% Small Clinics/Ind . 17% Other 8% Dialysis³ 5% 49 |

ibdroot \ projects \ IBD - NY \ dilates2022 \ 698484_1 \ Presentations \ 24. 2025.02.XX Fight Deck \ FINAL - to share with Cooley \ Dynavax Investor Presentation (May - 2025)_Print.pptx Deep Track Investor Presentation – page 13